CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

Horizon Rehab Center is proud to announce the launch of a free educational support group program for family members and loved ones of individuals struggling with addiction and mental health challenges ...

A new study reveals that heavy drinkers with depression experience the same level of buzz as those without depression, challenging the long-standing belief that alcohol's pleasurable effects diminish ...

A new study from the University of Chicago Medicine reveals that people with alcohol use disorder (AUD) and depression experience high levels of stimulation and pleasure when intoxicated, similar to ...

Community partners in Kenora, Ont., are preparing to launch one of two of the province's only Indigenous-led Homelessness and ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

All three cannabinoids reduced the electrical activity linked to Nav1.8, but CBG had the strongest effect. This suggests that CBG could be the most promising candidate for developing new pain ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...